Current Issue : October-December Volume : 2026 Issue Number : 4 Articles : 3 Articles
The mainstay of treatment for colorectal cancer (CRC) is chemotherapy, however side effects can lower quality of life, lead to unscheduled medical visits and interfere with drug administration. Through medication reconciliation, regimen-specific risk assessment, patient education, supportive care review, symptom monitoring and pharmacovigilance, clinical pharmacists can promote safer treatment. This narrative review summarizes research on the management, early identification and prevention of significant toxicities linked to irinotecan, oxaliplatin and fluoropyrimidines. Additionally, it takes into account patient-reported symptoms, pharmacogenetic risk assessment and the differentiation between clinical interventions recommended by guidelines and results attributed to services provided by pharmacists. Although demographics and outcome metrics are diverse and there is still no direct data specific to colorectal cancer, evidence from oncology pharmacy research suggests benefits for medication-related procedures. Pretreatment evaluation, cycle-based monitoring, triage and intervention, documentation and pharmacovigilance and reassessment comprise the five stages of the suggested closed-loop practice framework. Review completion, medication-related issue resolution, severe toxicity, urgent care use, treatment change and patient-reported symptom burden are all recommended evaluation metrics. The framework is a suggested practice model rather than a proven intervention; in order to determine its viability, resource needs and clinical efficacy, prospective study is necessary....
In older persons with colorectal cancer (CRC), frailty is a multifaceted state of decreased physiological reserve that can impact recovery, quality of life and treatment tolerance. The evidence on frailty assessment and CRC outcomes is summarized in this narrative review, with a focus on pharmacy-practice interventions that can convert evaluation into safer, more customized care. Although results vary by instrument, demographic and treatment environment, there is evidence linking frailty to postoperative morbidity, therapeutic toxicity, inadequate therapy, functional decline and lower survival. Medication burden, comorbidities, nutrition, cognition, function and social support needs can all be identified by a thorough geriatric evaluation. Medication reconciliation, screening for potentially inappropriate medications and interactions, organ-function-related dosage review, adherence support, toxicity education and communication with the multidisciplinary team are some ways pharmacists can help. There is encouraging evidence for pharmacist-led medication optimization in geriatric oncology, although it is not CRC-specific and is still scarce. While biomarkers, digital phenotyping and artificial intelligence are still under investigation, prehabilitation, sarcopenia assessment and long-term monitoring may enhance therapy. Oncological judgment and collaborative decision-making should be complemented, not replaced, by frailty-informed pharmacological care....
Globally, type 2 diabetes mellitus (T2DM) is a chronic metabolic disease that is spreading quickly and has significant clinical, financial and social costs. Medication non-adherence, drug-related problems (DRPs), adverse drug responses, polypharmacy and complex therapy regimens make it difficult to achieve adequate glycemic control even with the availability of effective pharmacological interventions. These difficulties often impair the efficacy of treatment, raise healthcare costs and hasten the onset of problems associated with diabetes. With active pharmacist involvement, pharmaceutical care has become a patient-centered practice approach that aims to maximize medication use and enhance therapeutic results. With a focus on medication adherence, DRP detection and resolution and their effects on patient outcomes, this study examines the role of pharmacological treatment in the management of type 2 diabetes. The pathophysiological basis of type 2 diabetes, traditional and modern antidiabetic treatments, factors that contribute to medication non-adherence, techniques for evaluating adherence and the clinical and financial ramifications of poor adherence are all covered in this study. Adverse drug responses, drug-drug interactions, polypharmacy, improper prescribing and medication errors are among the common DRPs that are further examined. Furthermore, a critical evaluation is conducted of pharmacist-led interventions, including pharmaceutical therapy management, patient education, therapeutic counselling, assistance for lifestyle modification, collaborative healthcare practice and telepharmacy. According to available data, pharmaceutical care interventions lower avoidable complications and healthcare utilization while improving medication adherence, glycemic control, drug safety, patient satisfaction and health-related quality of life. Precision pharmacotherapy, artificial intelligence, digital therapies and remote monitoring technologies are examples of emerging developments that present intriguing prospects to improve diabetes care. All things considered, pharmaceutical care continues to be a crucial part of all-encompassing T2DM management and greatly enhances clinical, humanistic and economic outcomes globally....
Loading....